Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Xuanzhu Biopharmaceutical Co's Pretax Margin % or its related term are showing as below:
HKSE:02575'
s Pretax Margin % Range Over the Past 10 Years
Min: -1027318.75 Med: -1848.92 Max: -473.67
Current: -473.67
HKSE:02575's Pretax Margin % is ranked worse than 95.2% of 958
companies
in the Drug Manufacturers industry
Industry Median: 7.02
vs HKSE:02575: -473.67
Xuanzhu Biopharmaceutical Co (HKSE:02575) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Xuanzhu Biopharmaceutical Co Pretax Margin % Related Terms
Xuanzhu Biopharmaceutical Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xuanzhu Biopharmaceutical Co Pretax Margin % Chart
Xuanzhu Biopharmaceutical Co Annual Data
Trend
Dec23
Dec24
Dec25
Pretax Margin %
-1,027,318.75
-1,848.92
-474.20
Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Pretax Margin %
0.00
-692.27
-3,167.27
-619.82
-397.30
HKSE:02575 vs ZTS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xuanzhu Biopharmaceutical Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xuanzhu Biopharmaceutical Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xuanzhu Biopharmaceutical Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Xuanzhu Biopharmaceutical Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a Pretax Margin % of -397.30% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. According to the industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #912 out of 958 companies in the Drug Manufacturers industry, placing it in the top 95.2%.
Is Xuanzhu Biopharmaceutical Co's Pretax Margin % too high?
Xuanzhu Biopharmaceutical Co's current Pretax Margin % is -397.30%. Based on the distribution chart, Xuanzhu Biopharmaceutical Co ranks #912 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #912 out of 958 companies for Pretax Margin %. This places Xuanzhu Biopharmaceutical Co in the lower half of its industry. The industry median Pretax Margin % is 7.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.02, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xuanzhu Biopharmaceutical Co's current Pretax Margin % is -397.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a current Pretax Margin % of -397.30%. The current Pretax Margin % is -397.30%. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (HKSE:02575), the current Pretax Margin % is -397.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score
Get the complete analysis for HKSE:02575
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02575 has been successfully added to your 
